Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Blueprint Medicines Corp stake
total: 670
Viking Global Investors BPMC trades
- Total transactions:
- 12
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 5
- Held since:
- 2018 Q3
- Held for:
- 11 quarters
- Latest activity:
- 2021 Q2
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any Blueprint Medicines Corp (BPMC) shares. To date, the estimated cost basis is nearly $63.94 for "buy" trades and estimated average "sell" price is $100.2. Viking Global Investors first purchased BPMC in 2018 Q3, initially acquiring 111,100 shares. Since the initial investment in Blueprint Medicines Corp (BPMC), Viking Global Investors has made 11 more transactions.
When did Ole Andreas Halvorsen sell Blueprint Medicines Corp (BPMC)?
Ole Andreas Halvorsen sold off the entire Blueprint Medicines Corp (BPMC) position in 2021 Q2.
When did Ole Andreas Halvorsen buy Blueprint Medicines Corp (BPMC)?
Ole Andreas Halvorsen first invested in Blueprint Medicines Corp (BPMC) in 2018 Q3 at the reported quarter-end price of $78.06 per share.
What's the cost basis of Viking Global Investors's BPMC stake?
The estimated cost basis for Blueprint Medicines Corp (BPMC) stake is around $63.94 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $63.94
- Weighted AVG sell price:
- $100.20
Ole Andreas Halvorsen's historical trades in Blueprint Medicines Corp
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q2
|
0.00%
|
0
|
$97.23
|
|
-100% (-213,050)
|
-0.06%
|
|
2021 Q1
|
0.06%
|
213,050
|
$97.23
|
$20,715,000
|
-21.87% (-59,631)
|
-0.02%
|
|
2020 Q4
|
0.08%
|
$112.15
|
-80.94% (-1,158,086)
|
|||
|
2020 Q3
|
0.48%
|
$92.70
|
-12.21% (-198,949)
|
|||
|
2020 Q2
|
0.55%
|
$78.00
|
+1.83% (+29,249)
|
|||
|
2020 Q1
|
0.49%
|
$58.48
|
+22.50% (+293,926)
|
|||
|
2019 Q4
|
0.49%
|
$80.11
|
+62.98% (+504,902)
|
|||
|
2019 Q3
|
0.31%
|
$73.47
|
+45.48% (+250,599)
|
|||
|
2019 Q2
|
0.23%
|
$94.33
|
-16.34% (-107,621)
|
|||
|
2019 Q1
|
0.30%
|
$80.05
|
-45.13% (-541,661)
|
|||
|
2018 Q4
|
0.37%
|
$53.91
|
+980.40% (+1,089,222)
|
|||
|
2018 Q3
|
0.05%
|
$78.06
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.